Physician
Radiation Oncology
Dr. Johnny Kao, MD
|
|
Give Review
Johnny Kao practices Radiation Oncology. He researched medicine at Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai is ranked 20/62 in Research/PrimaryCare. Johnny is a published doctor and has 46 publications published. The lastest was: 'Myeloid derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy.' Dr. Johnny Kao is registered with Medicare and accepts Medicare payments.
Publications
- Myeloid derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy.
- Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology.
- Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer.
- Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases : Final report of a prospective clinical trial.
- Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.
- Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck Cancer.
- Competing causes of death in patients with oropharyngeal Cancer treated with radiotherapy.
- gamma-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers.
- Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
- Prophylactic swallowing exercises in patients with head and neck Cancer undergoing chemoradiation: a randomized trial.
- Prognostic significance of p16 in locoregionally advanced head and neck Cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated r...
- Toxicity profile and clinical outcomes in locally advanced head and neck Cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
- Transoral robotic resection and reconstruction for head and neck Cancer.
- Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck Cancer.
- Outcomes for patients with extraprostatic prostate Cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy.
- Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.
- Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting.
- Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck Cancer.
- Targeting immune suppressing myeloid-derived suppressor cells in oncology.
- FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma.
- HPV-induced oropharyngeal Cancer, immune response and response to therapy.
- The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck Cancer.
- Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary...
- The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based Cancer therapies.
- Development of an automated gamma-H2AX immunocytochemistry assay.
- Correlation of positron emission tomography standard uptake value and pathologic specimen size in Cancer of the head and neck.
- Adjuvant radiotherapy and survival for patients with node-positive head and neck Cancer: an analysis by primary site and nodal stage.
- Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.
- (125)I monotherapy using D90 implant doses of 180 Gy or greater.
- Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
- Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
- Cellular response to DNA damage.
- In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276).
- Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
- Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
- Twice-daily reirradiation for recurrent and second primary head-and-neck Cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
- Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast Cancer: results from two consecutive phase I/II trials.
- Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?
- Hormone therapy and radiotherapy for early prostate Cancer: a utility-adjusted number needed to treat (NNT) analysis.
- Is there an association between multiple myeloma and prostate Cancer?
- Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
- Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.
- Penile erectile function after permanent radioactive seed implantation for treatment of prostate Cancer.
- The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
- Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome.
Schools
Mount Sinai School Of Medicine Of New York University
Beth Israel Med Center
University Of Chicago Hosps
Procedures Preformed
- Cancer Treatment
- Image-Guided Radiation Therapy (IGRT)
- Intensity-Modulated Radiation Therapy (IMRT)
Conditions Treated
- Cancer
- Pituitary Gland Cancer
- Vulvar Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- AvMed
- Blue Cross Blue Shield
- Capital District Physician's Health Plan (CDPHP) HMO
- Cigna
- Commercial Insurance Company
- Connecticare HMO
- Wellpath Preferred PPO
- Employer Group Open Access HMO
- Employer Group PPO
- Emblem Health
- GHI PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Group Health Cooperative
- Choice Care PPO
- MagnaCare PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Freedom Plan
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
- WellCare
Education
-
University of Chicago -
Mount Sinai Beth Israel -
Icahn School of Medicine at Mount Sinai
Drug Facts
| NPI NUMBER | 1639141476 | |
| NPPES Provider LastName | KAO | |
| NPPES Provider FirstName | JOHNNY | |
| NPPES Provider ZIPCode | 117954927 | |
| NPPES Provider State | NY | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 131.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 10.69 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639141476 |
| Last Name Of The Provider | KAO |
| First Name Of The Provider | JOHNNY |
| View All |
Similar Doctors
|
Dr. Eduard P. Kagan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neha Sharma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph G. Monge, MD
This Doctor is OpenDoctor Recommended.
|